Sabcomeline
Jump to navigation
Jump to search
Clinical data | |
---|---|
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number |
|
PubChem CID | |
IUPHAR/BPS | |
ChemSpider | |
UNII |
|
ChEMBL | |
Chemical and physical data | |
Formula | C10H15N3O |
Molar mass | 193.250 g·mol−1 |
3D model (JSmol) | |
|
Sabcomeline (Memric; SB-202,026) is a selective M1 receptor partial agonist that was under development for the treatment of Alzheimer's disease.[1] It made it to phase III clinical trials before being discontinued due to poor results.
See also
References
- ^ Loudon JM, Bromidge SM, Brown F, et al. (December 1997). "SB 202026: a novel muscarinic partial agonist with functional selectivity for M1 receptors". The Journal of Pharmacology and Experimental Therapeutics. 283 (3): 1059–68. PMID 9399977.
Categories:
- Articles with short description
- Short description matches Wikidata
- Drugs not assigned an ATC code
- Drugs with non-standard legal status
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Multiple chemicals in Infobox drug
- Chemicals using indexlabels
- Chemical articles with multiple CAS registry numbers
- Articles containing unverified chemical infoboxes
- Muscarinic agonists
- Nitriles
- Oximes
- Quinuclidines
- Experimental drugs